A parallel randomised phase II trial of CHOP chemotherapy with or without Bortezomib in relapsed mantle cell lymphoma
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Bortezomib Study
- 11 Sep 2013 Accrual to date is 55% according to United Kingdom Clinical Research Network.
- 19 May 2013 Accrual to date is 54% according to United Kingdom Clinical Research Network.
- 09 Feb 2013 Accrual to date is 53% according to United Kingdom Clinical Research Network.